Press release from Companies
Publicerat: 2021-11-18 20:08:18
“Correction: The year-end report for the period October 2020 – September 2021 lacked information on whether the interim report was subject to review by the company's auditor. The year-end report has not been subject to review by the company's auditor. Revised year-end report is available on CS MEDICA's website (https://www.cs-medica.com/) and as an attachment.”
Performance highlights Significant events during the fiscal year Significant events after the end of the fiscal year Financial statements 4 Quarter (DKK) 2020/2021 2019/2020 Net sales 2.093.921 302.478 Gross profit 875.489 53.366 Operating profit 263.779 21.439 Depreciation and amortisation - 602.191 - 190.869 Net financials - 52.549 - 62.575 Profit before taxes - 390.961 - 232.005 Net profit 364.763 - 254.798 Research and development costs 1.564.342 745.032 Cash flow 10.130.177 574.662 Financial Ratios Gross margin 42% 18% Operating margin 13% 7% Research and development i % of sales 75% 246% Net profit margin 17% -84% Fiscal Year (DKK) 2020/2021 2019/2020 2018/2019 Net sales 3.179.557 2.110.729 1.425.936 Gross profit 1.363.857 682.654 825.643 Operating profit 1.191.406 450.398 211.130 Depreciation and amortisation - 1.367.452 - 384.516 - 24.433 Net financials - 231.742 - 143.253 - 138.194 Profit before taxes - 407.788 - 77.371 48.503 Net profit 647.626 - 54.579 - 119.076 Cash and cash equivalents 9.996.085 296.884 4.169 Research and development costs 5.906.369 1.732.137 1.043.151 cash flow 9.699.201 691.217 86.195 Total Assets 27.411.166 5.436.210 3.279.071 Equity 24.147.361 87.241 - 1.759.061 Financial Ratios Gross margin 43% 32% 58% Operating margin 37% 34% 15% Research and development in % of sales 186% 82% 73% Net profit margin 20% -3% -8% Equity ratio 88% 2% 54% Share performance Basic earnings per share 0,05940 Total number of shares, 30 Sept 10.902.000 Closing share price 6,20 This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528) and the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person, on 18-11-2021 20:08 CET. The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.
For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/
CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.